Aortic Valve Stenosis
Conditions
Keywords
TAVI, Antiplatelet agent, Ticagrelor, Cerebrovascular events
Brief summary
Transcatheter Aortic Valve Implantation (TAVI) is now the method of choice to treat aortic stenosis in old and frail patients. Antiplatelet therapy must be associated for the procedure and during few weeks after implantation in the aim to minimize cerebral embolization. But for now, the best antiplatelet regimen has to be determined. In this context, investigators want to evaluate the safety of use of ticagrelor alone versus standardized therapy which involves lysine acetylsalicylate and clopidogrel. In this study, we will randomly compare 154 patients in each group in terms of early safety (30 days) after the procedure.
Detailed description
In spite of the use of the combination of lysine acetylsalicylate and clopidogrel during and after the procedure of TAVI, rates of stroke remains high, between 4 and 10% regarding the studies and registries. None of the therapeutics have regulatory authorisation for this indication. On the other hand, the rates of bleeding events are also high in this old and frail population. That is why, considering its pharmacological specificity, investigators hypothesize that ticagrelor, used alone, could be non-inferior on safety criteria than the combination of lysine acetylsalicylate and clopidogrel. Our study want to evaluate the safety profile of Ticagrelor alone (180 mg loading dose before intervention and 90 mg twice daily during 30 days after the procedure) compared to the standardized treatment combining lysine acetylsalicylate (75 mg before and 75 mg daily after the procedure) and clopidogrel (300mg loading dose before and 75 mg daily after the procedure). Patients will be followed during one month. Then they will be all placed under the usual antiplatelet treatment (clopidogrel and lysine acetylsalicylate for two additional months and then lysine acetylsalicylate alone lifelong).
Interventions
DRUGTicagrelor alone
180 mg loading dose before intervention and 90 mg twice daily during 30 days after the procedure
DRUGCombination lysine acetylsalicylate - clopidogrel
75 mg before and 75 mg daily after the procedure of lysine acetylsalicylate and 300mg loading dose before and 75 mg of clopidogrel daily after the procedure
Sponsors
University Hospital, Bordeaux
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Provision of informed consent prior to any study specific procedures * Female or male aged \> 18 years * Patient eligible for TAVI as recommended by French health care system authority (HAS)
Exclusion criteria
* Allergy, hypersensitivity, or contraindication to lysine acetylsalicylate, clopidogrel, ticagrelor, any anticoagulation or magnetic resonance imaging (MRI) or CT-scanner contrast agents * Use of Cytochrome P3a (CYP3a) inhibitor * Need for chronic anticoagulation * Previous percutaneous coronary intervention or acute coronary syndrome requiring dual antiplatelet therapy * Previous cardiac surgery for valve replacement * Prior stroke, transient ischemic attack (TIA) or known carotid stenosis \> 70% * Active pathological bleeding or gastric ulcer \< 3month * Known thrombocytopenia, anemia or any coagulopathy * Severe kidney or hepatic impairment * Hemodynamic instability * Refusal of Transfusion * Significant mental impairment * Inability to give informed consent or comply with study related procedures or high likelihood of being unavailable for follow-up * Pregnant or breastfeeding women * Women of childbearing potential without effective contraception (oestroprogestative, intrauterine devices) * Participant in another investigational drug or device study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patient presenting at least one event of the Valve Academic Research Consortium-2 (VARC2) composite endpoint | Day 30 | VARC2 composite endpoint : * All-cause mortality * All stroke (disabling and non-disabling) * Life-threatening or disabling bleeding * Acute kidney injury - Stage 2 or 3 (including renal replacement therapy) * Coronary artery obstruction requiring intervention * Major vascular complication * Valve-related dysfunction requiring repeat procedure |
| Number of patient died | Day 30 | — |
| Number of patient presenting stroke or Transient Ischemic Attack (TIA) | Day 30 | Diagnostic criteria: Acute episode of a focal or global neurological deficit with at least one of the following: change in the level of consciousness, hemiplegia, hemiparesis, numbness, or sensory loss affecting one side of the body, dysphasia or aphasia, hemianopia, amaurosis fugax, or other neurological signs or symptoms consistent with stroke Stroke: duration of a focal or global neurological deficit \>24 h; OR \<24 h if available neuroimaging documents a new haemorrhage or infarct; OR the neurological deficit results in death TIA: duration of a focal or global neurological deficit \<24 h, any variable neuroimaging does not demonstrate a new hemorrhage or infarct |
| Number of patient presenting life-threatening bleeding | Day 30 | Life-threatening bleeding: Fatal bleeding OR Bleeding in a critical organ, such as intracranial, intraspinal, intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome OR Bleeding causing hypovolaemic shock or severe hypotension requiring vasopressors or surgery OR Overt source of bleeding with drop in haemoglobin \>5 g/dL or whole blood or packed red blood cells (RBCs) transfusion \>4 units |
| Number of patients presenting post-TAVI acute kidney failure stage 2 or 3 as assessed by VARC2 | Day 30 | — |
| Number of patients presenting angiographic or echographic evidence of a new, partial or complete, obstruction of a coronary ostium, either by the valve prosthesis itself, the native leaflets, calcifications, or dissection | Day 30 | — |
| Number of patients presenting major vascular complications | Day 30 | — |
| Number of patients requiring a new procedure like Balloon Aortic valvuloplasty (BAV), new procedure of TAVI or Surgical aortic valve replacement (SAVR) | Day 30 | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of patients presenting at least one conduction disturbance or arrhythmias | Day 30 |
| Number of patients presenting at least one other TAVI related complication | Day 30 |
| Number of patients presenting at least one bleeding event (life-threatening, major or minor) | Day 30 |
| Number of patients with good biological efficiency of the antiplatelet therapy assessed by VerifyNow (VN) | Day 30 |
| Number of patients with new cerebral event assessed by brain Magnetic Resonance Imaging (MRI) | Day 5 |
| Number of high-intensity transient signals (HITS) assessed by transcranial Doppler | Day 1 |
| Assessment of neurological status by the score of Mini Mental State Examination (MMSE) | At baseline and day 30 |
| Assessment of neurological status by the Dubois's 5 words test | At baseline and day 30 |
| Assessment of neurological status by the Geriatric Depression Scale (GDS) | At baseline and day 30 |
| Assessment of neurological status by the basic Activities of Daily Living (ADL) questionnaire | At baseline and day 30 |
| Assessment of neurological status by the Instrumental Activities of Daily Life (IADL) questionnaire | At baseline and day 30 |
| Assessment of neurological status by the Short Form Health Survey (SF-12) questionnaire | At baseline and day 30 |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORLionel LEROUX, Dr
University Hospital, Bordeaux
Outcome results
None listed